EN | RU
EN | RU

Help Support

Back

MTX found to be effective primary anchor drug in RA, irrepective of autoantibody status

MTX found to be effective primary anchor drug in RA, irrepective of autoantibody status MTX found to be effective primary anchor drug in RA, irrepective of autoantibody status
MTX found to be effective primary anchor drug in RA, irrepective of autoantibody status MTX found to be effective primary anchor drug in RA, irrepective of autoantibody status

What's new?

Autoantibody status is not associated with early remission and good physical function, so RA treatment should not be always tailored to autoantibody status in patients receiving MTX.

A recent study published in Journal Rheumatology recommended the use of methotrexate (MTX) as an initial treatment strategy despite autoantibody status. Before this analysis, the connection of autoantibody status with treatment response to MTX was unpredictable. This study used real-world data to assess this relationship.

An international observational database, METEOR was used to choose patients who initially administered with MTX. A total of 1826 patients were classified into autoantibody negative and autoantibody-positive groups. Further, Cox-proportional hazards regression was used to evaluate the impact of autoantibody status on the probability of obtaining remission within 3 to 6 months.

A total of 318 patients obtained the DAS remission; 18% from the negative group and 17% from the positive group. This reflected no association of remission with autoantibody positivity. Also, no association was seen between autoantibody-positivity and HAQ < 0.5. Comparable verdicts were observed when stratified for MTX monotherapy or combination therapy. Further, 530 out of 1590 patients attained good physical function.  All these findings showed no link between early remission in newly diagnosed RA-patients receiving MTX and autoantibody status, which indicates MTX as an efficacious treatment approach for rheumatoid arthritis treatment. 

Source:

Rheumatology

Article:

Autoantibody status is not associated with early treatment response to first-line Methotrexate in patients with early rheumatoid arthritis.

Authors:

Jacqueline S Dekkers et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: